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ABSTRACT Asthma is a chronic, inflammatory lung disease affecting around 235 million people
worldwide. Conventional medications in asthma are not curative and patients have significant concerns
regarding their side-effects. Consequently, many asthma patients turn to complementary and alternative
medicine (CAM) for a more holistic approach to care. We systematically reviewed the available evidence
on the effectiveness of CAM in the management of asthma in adults.
We searched the MEDLINE, EMBASE, CINAHL, AMED and Cochrane databases for randomised
controlled trials published in English between 1990 and 2016 investigating the effectiveness of oral or
topical CAM in asthmatic adults. The quality of the studies was assessed using the Cochrane Risk of Bias
Assessment Tool.
In all, 23 eligible trials were identified covering 19 different CAMs. Overall, there was limited evidence on
the effectiveness of CAM in adult asthma as most CAMs were only assessed in a single trial. CAMs with
multiple trials provided null or inconsistent results. Many of the trials were rated as having high risk of bias.
The existing evidence is insufficient to recommend any of the oral and topical CAMs in the
management of asthma in adults.
Introduction
Asthma is a chronic, inflammatory lung disease affecting around 235 million people worldwide [1].
Conventional medications in asthma are not curative and patients have significant concerns regarding
their side-effects. Consequently, complementary and alternative medicine (CAM) is increasingly used in
the management of asthma. Evidence suggests that up to 79% of patients use CAM [2]. The “natural”,
noninvasive appeal of CAM combined with previous positive experience, consultation quality and personal
beliefs are cited as the main reason for CAM use in asthma patients [3].
There have been several systematic reviews to assess the use of CAM in the management of asthma [4–9].
However, the existing reviews have been limited by poor methodology (study design and outcome
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measures) and conflicting results, thus preventing any definitive conclusions. Also, these reviews have
made a broad assessment of CAM use amongst asthmatics and have not always isolated practitioner-based
CAM from complementary medicines and, therefore, have not been able to attribute any benefit to one or
the other. This review aims to address these problems by focusing on specific complementary medicines in
the adult asthmatic population with clear outcome measures related to efficacy.
Methods
The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and
recommendations of the Cochrane Collaboration were followed for the reporting of this review
(www.prisma-statement.org).
Eligibility criteria
Studies were included if they: 1) were a randomised controlled trial (RCT) published in English between
1990 and 2015; 2) investigated a self-administered oral or topically applied CAM (i.e. not
practitioner-based therapy); and 3) included only asthmatic participants aged ⩾18 years with a diagnosis
of asthma by a general practitioner, consultant or standard guidelines (e.g. British Thoracic Society). Trials
with healthy controls, animals, pregnant women or children were excluded.
Information sources
During October 2016 the following databases were searched: AMED, EMBASE, MEDLINE and the
Cochrane Library. The most recent search was conducted on October 7, 2016. References in each of the
identified articles were further screened for relevant articles.
Search
The database search was constructed around three themes: 1) identification of relevant oral and topical
interventions using 76 names of CAMs commonly taken in asthma; 2) identification of the disease of
interest using “asthma” or other relevant terms; and 3) identification of relevant study design (RCTs). The
search terms were adapted to suit each database and connected by Boolean terms “OR” and “AND”. The
details of the search strategy can be found in the supplementary material.
Study selection
Study titles were double screened (by both authors) and irrelevant or duplicate articles removed. The
abstracts of the remaining articles were reviewed using the selection criteria. During this stage, the criteria
were adapted to exclude trials involving magnesium sulfate, biologic agents and monoclonal antibodies, as
these form part of the national management guidelines and therefore do not conform to the World Health
Organization definition of CAM. If the abstract did not provide sufficient information then the full text
article was reviewed. Trials were excluded where the intervention was not self-administered or the patient
group had comorbid lung disease. The identification of relevant studies is presented in figure 1.
Data extraction and items
Data from each eligible study were extracted and details of the author, date, country, setting, participant
characteristics, intervention, control, duration of intervention, outcome measures and outcomes were
placed in summary tables. The risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool
[10]. An “unclear” judgement was made if insufficient detail was provided. The raw data on change of
outcome measures from each study was summarised in table form to enable easier comparison of outcome
measures between studies. The results are summarised in tables 1 and 2.
Outcome measures and analysis
The primary measure was lung function. Secondary outcomes included quality of life, asthma control,
medication usage, healthcare utilisation and adverse effects.
For the meta-analysis, as all data were continuous, end-point scores were expressed as mean differences or
standardised mean differences (SMDs) with associated 95% confidence intervals. Meta-analysis was
performed using RevMan 5.3 software.
Results
The literature search revealed a total of 1263 non-duplicate records. A total of 967 articles were excluded
after title screening and 296 abstracts were reviewed. At this stage, 238 articles were excluded, including 28
additional duplicates, leaving 101 full text articles to be assessed for eligibility. These 101 articles included
43 additional studies identified from the bibliographies of already finalised articles. After examination of the
full text, 78 more articles were excluded. 23 full text articles were included in the review. Two trials
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appeared twice, as they both investigated multiple interventions [13, 24]. The methodological quality of the
included trials varied. Details of the risk of bias assessment for each trial are summarised in table 3 and 4.
CAM tested in single trials
Curcumin
Curcumin is a natural product from the rhizome turmeric (Curcuma longa) [11]. A trial of 60 adults aged
18–55 years with bronchial asthma randomised participants to receive either 500 mg curcumin twice daily
and standard asthma therapy or standard asthma therapy alone for 30 days [13]. Lung function was
assessed using pre- and post-bronchodilator forced expiratory volume in 1 s (FEV1). The study reported
significant improvement in FEV1 in the intervention group compared to the control group (p<0.05).
New Zealand green-lipped mussel
This CAM contains the lipid extract of Perna canaliculus (omega-3 fatty acids) [12]. A total of 46 adults
aged 18–65 years with mild-to-moderate atopic asthma were randomised into either an intervention or
control group for 8 weeks [12]. The intervention was two 150-mg capsules twice daily containing 50 mg
omega-3 polyunsaturated fatty acids and 100 mg olive oil plus inhaled salbutamol as rescue medication.
The control group took two placebo capsules twice daily containing 150 mg olive oil and rescue salbutamol
when required. FEV1 and peak expiratory flow rate (PEFR) were used to measure lung function. Morning
PEFR was significantly improved in the intervention group compared to placebo (p<0.001). There was no
difference in FEV1 and evening PEFR.
Solanum xanthocarpum and Solanum trilobatum
In this trial, 60 adults aged 18–50 years with mild-to-moderate asthma took part in a single day trial [13].
Participants received either 300 mg oral Solanum xanthocarpum or 300 mg oral Solanum trilobatum
(CAM commonly used in southern Indian Siddha medicine) as the intervention and 200 mg deriphylline
or 4 mg salbutamol as the control. Lung function was assessed using forced vital capacity (FVC), FEV1
and PEFR. Compared to salbutamol, post-intervention FEV1 and FVC was significantly greater with
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FIGURE 1 Flow chart of article selection process for this review.
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S. xanthocarpum (p<0.05). PEFR improvement was significantly greater compared to deriphylline
(p<0.01). There was no significant difference between the S. trilobatum intervention group and the two
controls (salbutamol and deriphylline).
Coenzyme Q10
The antioxidants coenzyme Q10 and α-tocopherol were assessed in this crossover trial of 41 adults aged
25–50 years with mild-to-moderate bronchial asthma. A combination of 120 mg of coenzyme Q10 gel,
TABLE 1 Summary of results for complementary and alternative medicine (CAM) tested in single trials
CAM Intervention group Control group Treatment
duration
Outcome First author [ref.] Country
Curcumin “Standard” asthma
treatment + 500 mg
curcumin twice daily
“Standard” asthma
treatment
4 weeks Difference (+): pre/
post-bronchodilator FEV1
No difference (−): clinical
symptom severity, adverse events
ABIDI [11] India
New Zealand
green-lipped
mussel
Two 150 mg capsules of
New Zealand green-lipped
mussel twice daily
Two 150 mg
placebo capsules
twice daily
8 weeks Difference (+): mean daytime
wheeze, mean morning PEFR
No difference (−): nocturnal
awakening, use of short-acting
inhaled β2-agonists, mean FEV1,
evening PEFR
EMELYANOV [12] Russia
Solanum
xanthocarpum
Solanum xanthocarpum
300 mg orally once daily
Salbutamol 4 mg
once daily or
deriphylline 220 mg
1 day Difference (+): FVC, FEV1, PEFR
No difference (−): none
GOVINDAN [13] India
Solanum
trilobatum
Solanum trilobatum
300 mg orally once daily
Salbutamol 4 mg
once daily or
deriphylline 220 mg
1 day Difference (+): none
No difference (−): FVC, FEV1,
PEFR
GOVINDAN [13] India
Coenzyme Q10 120 mg Coenzyme Q10 +
400 mg α-tocopherol +
250 mg vitamin C +
“standard” asthma
treatment
“Standard”
asthma treatment
32 weeks
(16-week
crossover)
Difference (+): total usage of
corticosteroids
No difference (−): FEV1,
FEV1/FVC, PEFR
GVOZDJAKOVA [14] Slovakia
Selenium Daily oral 100 μg sodium
selenite
Daily oral placebo 14 weeks Difference (+): none
No difference (−): FEV1, PEFR
HASSELMARK [15] Sweden
Auranofin 3 mg oral auranofin twice
daily
3 mg oral placebo
twice daily
12 weeks Difference (+): none
No difference (−): FEV1, FVC
HONMA [16] Japan
Pyridoxine
(vitamin B6)
300 mg oral pyridoxine
(mixed with lactose) daily +
oral prednisolone
Oral placebo daily +
oral prednisolone
9 weeks Difference (+): none
No difference (−): morning/
evening PEFR, FEV1, morning/
evening symptom scores,
nocturnal asthma awakening
KASLOW [17] USA
Aqueous extract
of propolis
13% aqueous extract of
propolis in water orally
once daily + oral
theophylline
Placebo sachet in
water orally once
daily + oral
theophylline
8 weeks Difference (+): need for rescue
medication, number of nocturnal
attacks per week, FVC, FEV1,
PEFR
No difference (−): none
KHAYYAL [18] Egypt
Vitamin E Two capsules (250 mg
vitamin E + soya bean oil)
Two placebo
capsules (gelatine
base)
6 weeks Difference (+): none
No difference (−): FEV1, FVC,
mean morning peak flow,
symptom score, bronchodilator
use
PEARSON [19] UK
AKL1# Two AKL1 capsules
twice daily
Two placebo
capsules twice daily
36 weeks Difference (+): none
No difference (−): PEFR,
FEV1, AQLQ, ACQ, LCQ
THOMAS [20] UK
Lactose powder 6.25 mg, 12.5 mg, 25 mg,
50 mg or 100 mg of lactose
powder in rotadisk
Inhaled placebo in
rotadisk
1 day Difference (+): none
No difference (−): FEV1
THOREN [21] Sweden
TJ-96 2.5 g of oral Saiboku-to
TJ-96 three times daily
Oral placebo three
times daily
8 weeks Difference (+): symptom score
No difference (−): FEV1
URATA [22] Japan
Pingchuan Yiqi
Granule
Two oral Pingchuan Yiqi
Granule capsules three
times daily
Four oral Ruyi
Dingchuan pills
three times daily
1 week Difference (+): none
No difference (−): FEV1, PEFR
ZHANG [23] China
FEV1: forced expiratory volume in 1 s; PEFR: peak expiratory flow rate; FVC: forced vital capacity; AQLQ: Asthma Quality of Life Questionnaire;
ACQ: Asthma Control Questionnaire; LCQ: Leicester Cough Questionnaire. #: Picrorrhiza kurroa, Zingiber officinale, Ginkgo biloba and apocynin.
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400 mg α-tocopherol, 250 mg vitamin C and standard asthma therapy were compared with standard
asthma therapy (inhaled corticosteroids and short-acting β-agonists) alone. Participants received either the
intervention or control for 16 weeks before crossing over to the other trial arm. Lung function was
assessed with FEV1 and PEFR; neither of which showed significant changes compared to the placebo.
TABLE 2 Summary of results for complementary and alternative medicines tested in multiple trials
Intervention group Control group Treatment
duration
Outcome First author [ref.] Country
Magnesium
Daily oral magnesium
amino chelate 450 mg
(27.6 mmol) + oral
vitamin C placebo
Daily oral vitamin C placebo +
oral magnesium placebo
16 weeks Difference (+): none
No difference (−):
FEV1, FVC, PEFR,
symptom control,
bronchodilator use
FOGARTY [24] UK
400 mg oral magnesium
supplement daily
Oral placebo daily 8 weeks Difference (+): asthma
symptom score
No difference (−):
FEV1, PEFR,
bronchodilator use
HILL [25] UK
Vitamin C
Daily oral vitamin C 1 g
(5.6 mmol) + oral
magnesium placebo
Daily oral vitamin C placebo +
oral magnesium placebo
16 weeks Difference (+): none
No difference (−):
FEV1, FVC, PEFR,
symptom control,
bronchodilator use
FOGARTY [24] UK
1000 mg oral vitamin C
daily + “standard”
asthma treatment
Oral placebo daily + “standard”
asthma treatment
4 weeks Difference (+): none
No difference (−):
FEV1, FVC, FEV1/FVC
NADI [26] Iran
n-3 Polyunsaturated fatty acids
Two fish oil capsules
(455 mg EPA + 325 mg
DHA + 10 mg vitamin E)
once daily
Two capsules of amide
once daily
2 weeks Difference (+): none
No difference (−):
FEV1, ACQ score
MOREIRA [27] Portugal
10–20 g of perilla seed oil
daily (n-3 fatty acids)
10–20 g of corn oil daily
(n-6 fatty acids)
4 weeks Difference (+): FVC, FEV1
No difference (−): PEFR
OKAMOTO [28] Japan
ASHMI
Oral ASHMI 600 mg,
1200 mg or 1800 mg
twice daily + “standard
asthma treatment”
Oral placebo twice daily +
“standard asthma treatment”
1 week KELLY-PIEPER [29] USA
Four oral ASHMI capsules
3 times a day +
prednisone placebo
Prednisone 20 mg once daily +
ASHMI placebo
4 weeks Difference (+): FEV1, PEFR
No difference (−):
Symptom score, use of
bronchodilators
WEN [30] China
Vitamin D
Six 2-monthly oral doses
6 mL vigantol oil
containing 3 mg (120
000 IU) vitamin D3
Six 2-monthly oral doses 6 mL
vigantol oil containing 6 mL
organolpetically identical
placebo
52 weeks Difference (+): SGRQ
score
No difference (−): ACT
score, FEV1, PEFR,
symptom control
MARTINEAU [31] UK
2 weeks 0.25 mcg oral
calcitrol twice daily then
2 weeks combination
with oral prednisolone
2 weeks organoleptically
identical lactose placebo twice
daily then 2 weeks combination
with oral prednisolone
10 weeks No difference (−): ACQ
score, change in FEV1
NANZER [32] UK
28 weeks 4000 IU once
daily with ciclesonide
320 mcg controller
therapy
28 weeks placebo with
ciclesonide 320 mcg controller
therapy
32 weeks No difference (−): lung
function (FEV1, PEFR),
asthma control/symptom
score
CASTRO [33] USA
ASHMI: anti-asthma herbal medicine intervention; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; PEFR: peak expiratory flow
rate; ACQ: Asthma Control Questionnaire; SGRQ: St George’s Respiratory Questionnaire; ACT: Asthma Control Test; EPA: eicosapentaenoic acid.
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TABLE 3 Summary of the trials of complementary and alternative medicines (CAM) with significant positive outcomes
CAM Intervention group Control group Treatment
duration
Sample
size n
Positive
outcome#
Intervention
group
Control group p-value Overall risk of
bias score¶
First author
[ref.]
Country
Curcumin “Standard” asthma
treatment +
500 mg curcumin
twice daily
“Standard”
asthma
treatment
4 weeks 60 Change in
FEV1
−0.72±0.69 −0.83±0.63 <0.05 Low ABIDI [11] India
New Zealand
green-lipped mussel
Two 150 mg
capsules of New
Zealand
green-lipped
mussel twice daily
Two 150 mg
placebo
capsules twice
daily
8 weeks 46 Mean morning
PEFR
47.0±11.7 −33.4±6.2 <0.001 Low EMELYANOV [12] Russia
Solanum xanthocarpum Solanum
xanthocarpum
300 mg orally once
daily
Salbutamol
4 mg once daily
or deriphylline
220 mg
N/A (1 day) 60 % increase
predicted FVC,
% increase
predicted
FEV1, %
increase PEFR
22.4±2.3
25.3±2.7
20.8±2.4
32.2±3.7
41.9±6.9
37.5±6.0
<0.05
<0.05
<0.01
Unclear GOVINDAN [13] India
Aqueous extract
of propolis
13% aqueous
extract of propolis
in water orally
once daily + oral
theophylline
Placebo sachet
in water orally
once daily +
oral
theophylline
8 weeks 45 % increase
FVC, %
predicted
FEV1, %
increase PEFR
18.7%
29.5%
29.8%
Not available
Not available
Not available
0.0001
0.0001
0.0001
Unclear KHAYYAL [18] Egypt
n-3 Polyunsaturated
fatty acids
10–20 g of perilla
seed oil daily (n-3
fatty acids)
10–20 g of corn
oil daily (n-6
fatty acids)
4 weeks 14 FVC, %
predicted FEV1
Exact data not
available
96.7 (85.4–108.0)
Exact data not
available
90.9 (75.9–105.8)
<0.05
<0.05
Unclear OKAMOTO [28] Japan
ASHMI Four oral ASHMI
capsules 3 times a
day + prednisone
placebo
Prednisone
20 mg once
daily + ASHMI
placebo
4 weeks 91 Mean change
in FEV1
and PEFR
19.4±5.5
20.1±5.6
23.2±8.9
23.0±7.5
0.02
0.04
Unclear WEN [30] China
ASHMI: anti-asthma herbal medicine intervention; FEV1: forced expiratory volume in 1 s; PEFR: peak expiratory flow rate; FVC: forced vital capacity. #: lung function only; ¶: the risk of
bias was assessed using the Cochrane Risk of Bias Assessment Tool [10]. An “unclear” judgement was made if insufficient detail was provided. The mean judgement from the seven
domains was used to determine the “overall” score.
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Selenium
In this small trial, 24 adults aged 18–75 years with intrinsic asthma were randomised to receive either
100 µg of oral sodium selenite (containing chemical element selenium) or oral placebo for 14 weeks [15].
FEV1 and PEFR were used to measure lung function. There was no statistically significant difference
between the intervention and control groups for these parameters.
Auranofin
Auranofin is an oral gold compound that was used as the intervention in this 12-week trial of 19 adults
with asymptomatic bronchial asthma [16]. Participants received either 3 mg oral auranofin twice daily or
3 mg placebo twice daily. FEV1 and FVC were outcome measures of interest. There was no statistically
significant difference between the auranofin and placebo group.
Pyridoxine
31steroid-dependent adults aged 19–56 years with a diagnosis of asthma were included in this 9-week trial
[17]. Participants were randomised to take 300 mg oral pyridoxine (vitamin B6 mixed with lactose) once daily
alongside oral prednisolone or daily oral placebo and prednisolone. FEV1 and PEFR were measured. Although
morning PEFR improved in the pyridoxine group in the last 2 weeks of the trial (p=0.02), compared to the
placebo it was insignificant. There were no significant differences in any other outcome measure.
Aqueous extract of propolis
45 adults aged 19–52 years with a 2–5 year history of mild-to-moderate asthma were randomised to either
the intervention or control arm [18]. Participants received a sachet of either 13% aqueous extract of
propolis or placebo suspended in water as a milk drink once daily with oral theophylline for 2 months.
Lung function was measured by FVC, FEV1 and PEFR. There was a significant improvement in FVC, FEV1
and PEFR during the trial period (p=0.0001). However, these results were not compared to the placebo and
therefore the effectiveness of aqueous extract of propolis compared to the placebo remains unclear.
Vitamin E
This high-quality trial randomised participants to receive either two capsules containing 250 mg of natural
vitamin E (D-α-tocopherol) in soya bean oil or two capsules of gelatine-based placebo daily for 6 weeks
[19]. The 64 participants had physician-diagnosed asthma and were aged between 18 and 60 years. Each
was using at least one dose of inhaled corticosteroid daily. FEV1, FVC and morning PEFR were used to
assess lung function. There was no significant difference between the placebo and vitamin E groups in any
outcome measure.
AKL1
AKL1 is a botanical product containing Picrorrhiza kurroa, Zingiber officinale, Ginkgo biloba and
apocynin [20]. In this crossover trial, 32 participants were randomised to receive either two AKL1 capsules
twice daily or two placebo capsules twice daily for 12 weeks before an 8 week wash-out period and a
further 12 week crossover period. Lung function was measured by PEFR and FEV1. There was no
statistically significant difference between the two groups.
Lactose powder
18 participants aged 18–57 years completed this trial. Four rotadisks were provided to each, containing
either placebo (control), 6.25 mg, 12.5 mg, 25 mg, 50 mg or 100 mg lactose in total [21]. All were to be
self-administered (via inhalation) in quick succession during one study visit. On a separate visit, all
participants took another four rotadisks containing only placebo. FEV1 was used to assess lung function.
No significant difference was observed in FEV1 between the control and intervention arms.
TJ-96
TJ-96 (or Saiboku-to) is a herbal compound used in kampo medicine [22]. 32 participants with
mild-to-moderate atopic asthma were randomised to receive either 2.5 g of oral TJ-96 three times daily or
oral placebo three times daily for 8 weeks. Outcome measures included FEV1 and FVC, which did not
improve significantly when compared to placebo.
Pingchuan Yiqi Granule
This is a Chinese compound containing ephedra herb, red ginseng, Japanese Yam rhizome, apricot seed,
magnolia bark, common perilla leaf, thorowax root, tangerine peel and liquorice root [23]. In this 7-day
trial of 80 adults aged 33–60 years with mild-to-moderate bronchial asthma, participants were randomised
to receive either two oral Pingchuan Yiqi Granule capsules three times daily or four control capsules three
times daily. The control was Ruyi Dingchuan, another Chinese compound, containing gecko, toad venom,
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milkvetch root, earthworm, ephedra herb, asiabell root, apricot seed, gingko seed, immature bitter orange,
asparagus root, schisandra fruit, lilyturf root, tatarian aster root, rhizome, stemona root, Barbary wolfberry,
prepared rehmannia root, polygala root, pepperweed seed, hindu datura dried flower, gypsum fibrosum,
and honey grilled liquorice root [23]. Lung function was assessed through FEV1 and PEFR. There was no
significant difference between the control and intervention groups for these outcomes.
CAM tested in multiple trials
Magnesium
The first trial of 234 participants aged 18–60 years were randomised to receive either 450 mg daily oral
magnesium amino chelate and oral vitamin C placebo or daily oral magnesium and vitamin C placebo for
16 weeks [24]. FEV1, FVC and PEFR were used to assess lung function. There was no significant
difference between the control and intervention groups for these outcomes.
The second trial of 17 steroid-dependant asthmatic adults aged 25–60 years observed the effect of 400 mg
daily oral magnesium versus daily placebo on FEV1 and PEFR [25]. This 8-week crossover trial had a
1-week run-in period followed by 3 weeks of intervention, 1 week of wash out and 3 more weeks of
intervention. The outcome measures of interest were insignificant. Meta-analysis was conducted for FEV1.
Vitamin C
Neither of the two included trials found any difference in outcome measures between the control and
vitamin C groups. The first trial of 234 participants aged 18–60 years were randomised to receive either
1 g daily oral vitamin C and oral magnesium placebo or daily oral vitamin C and magnesium placebo for
16 weeks [24]. Lung function was measured with FEV1, FVC and PEFR. The second trial of 60 adults aged
30–57 years with severe bronchial asthma measured FEV1, FVC and FEV1/FVC [26]. For 1 month,
participants continued standard asthma therapy with either 1 g oral vitamin C daily or oral placebo. There
was no significant difference in any of the outcomes between the intervention and control group.
Meta-analysis was conducted for FEV1 and FVC.
n-3 Polyunsaturated fatty acids
20 females aged 24–46 years with stable, persistent asthma were randomised to receive two capsules of
amide once daily (as the control) or two fish-oil capsules containing 455 mg eicosapentaenoic acid,
325 mg docosahexaenoic acid and 10 mg vitamin E daily [27]. This 2-week trial measured FEV1, which
did not change significantly.
The second trial observed the effect of 10–20 g of perilla seed oil daily (n-3 polyunsaturated fatty acid) on
PEFR, FEV1 and FVC compared to 10–20 g of corn oil daily (n-6 fatty acids) [28]. 14 adults aged 22–84
years with moderate asthma were recruited to this 4-week trial. Participants received oral theophylline,
inhaled short-acting β-agonists and steroids regularly. A significant difference was noted between the
control and intervention groups with regard to FEV1 (p<0.05) and FVC (p<0.05).
ASHMI
ASHMI (anti-asthma herbal medicine intervention) is a Chinese herbal formula containing Ku-Shen
(Sophora flavescens), Gan-Cao (Glycyrrhiza uralensis) and Ling-Zhi (Ganoderma lucidum). The first of the
two included studies did not provide details of their lung function results so could not be fully analysed
[30]. The 20 participants in this trial, aged 18–55 years received 600 mg, 1200 mg or 1800 mg oral ASHMI
twice daily with standard asthma therapy for 1 week. The control was a corn starch capsule taken twice
daily alongside standard asthma treatment.
The second trial of 91 adults aged 18–65 years with moderate-to-severe asthma took either four ASHMI
capsules three times a day with a prednisone placebo or 20 mg prednisone once daily with an ASHMI
placebo [29]. This 4-week trial assessed lung function using FEV1 and PEFR, which improved significantly
throughout the trial (p=0.02 and p=0.04, respectively).
Vitamin D
The three included trials found no difference in lung function between control and vitamin D groups. The
first trial of 250 participants aged 16–80 years were randomised to receive 6 mL of vigantol oil containing
either 3 mg vitamin D3 or 6 mL organoleptically identical placebo every 2 months for 12 months [31]. FEV1
and PEFR were used to assess lung function. No significant difference was observed in either outcome. The
second trial of 23 asthmatic adults were randomised to receive either 4 weeks of 0.25 mcg oral calcitrol or
lactose placebo twice-daily following 2 weeks of oral prednisolone and a 4-week wash-out period [32].
Adjunctive oral prednisolone was also taken in the last 2 weeks of the trial. FEV1 was used to assess lung
function; no significant comparisons were found between groups. The final trial assessed lung function in
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408 asthmatic adults taking 4000 IU of oral vitamin D for 28 weeks alongside regular ciclenoside controller
therapy [33]. No significant results were found for FEV1 or PEFR when comparing groups.
Meta-analysis
Magnesium
Data from two studies [24, 25] were pooled to assess the effectiveness of magnesium on FEV1 (figure 2).
The result indicated no statistically significant differences in FEV1 between the intervention and the control
group (mean difference −0.06, 95% CI −0.26–0.14). Data could not be pooled for any other outcomes.
Vitamin C
Data from two studies [11, 26] were pooled to assess the effectiveness of vitamin C on FEV1 (figure 3), which
indicated no statistically significant differences in FEV1 between the intervention and the control group (mean
difference −0.18, 95% CI −0.54–0.19). Also, no statistically significant differences in FVC were found between
the intervention and the control group (mean difference −0.11, 95% CI −0.34–0.11) (figure 4).
Vitamin D
Data from two studies [31, 32] were pooled to assess the effectiveness of vitamin D on FEV1 (figure 5).
The result indicated no statistically significant differences in FEV1 between the intervention and the
control group (mean difference 1.58, 95% CI −3.28–6.44).
Quality of evidence
A large number of included studies were of poor quality. Individual studies were small, ranging from 14 to
232 participants. 12 trials did not detail sequence generation [13, 14, 16–18, 20–22, 26, 28–30] and
20 trials did not adequately detail allocation concealment [11–26, 28, 29, 30, 33]. Complete blinding
(of participants, personnel and outcome assessors) was only reported in two trials [19, 32]. 11 trials had
incomplete outcome data [13, 14, 16, 20, 22, 23, 25, 26–29] and four selective reporting [14, 15, 28, 29].
First author
[ref.] Total
WeightMagnesium Placebo
Mean ± SD L Mean ± SD L
Mean difference
IV fixed (95% CI) L
Mean difference
IV fixed (95% CI) L
FOGARTY [24]
HILL [25]
Heterogeneity. Chi2=0.14, df=1 (p=0.71); I2=0% –1 10–0.5 0.5
2.68±0.68
2.49±0.68
80
17
Total
82
17
76.8%
23.2%
–0.08 (–0.31–0.15)
0.01 (–0.41–0.43)
2.76±0.81
2.48±0.56
Total (95% CI)
Test for overall effect: Z=0.57 (p=0.57) Favours placebo Favours magnesium
97 99 100.0% –0.06 (–0.26–0.14)
FIGURE 2 Forest plot of comparison: magnesium versus control (outcome: forced expiratory volume in 1 s).
First author
[ref.] Total
WeightPlaceboVitamin C
Mean ± SD L Mean ± SD L
Mean difference
IV random (95% CI) L
Mean difference
IV random (95% CI) L
FOGARTY [24]
NADI [26]
Heterogeneity. Tau2=0.04, Chi2=2.79, df=1 (p=0.09); I2=64% –1 10–0.5 0.5
2.75±0.81
1.44±0.59
72
30
Total
82
30
55.4%
44.6%
–0.01 (–0.27–0.25)
–0.38 (–0.73–0.03)
2.76±0.81
1.82±0.78
Total (95% CI)
Test for overall effect: Z=0.95 (p=0.34) Favours placebo Favours vitamin C
102 112 100.0% –0.18 (–0.54–0.19)
FIGURE 3 Forest plot of comparison: vitamin C versus control (outcome: forced expiratory volume in 1 s).
First author
[ref.] Total
WeightVitamin C Placebo
Mean ± SD L Mean ± SD L
Mean difference
IV fixed (95% CI) L
Mean difference
IV fixed (95% CI) L
FOGARTY [24]
NADI [26]
Heterogeneity. Chi2=0.22, df=1 (p=0.64); I2=0% –1 10–0.5 0.5
3.66±0.99
2.16±0.54
72
30
Total
82
30
50.6%
49.4%
–0.06 (–0.38–0.26)
–0.17 (–0.49–0.15)
3.72±1.04
2.33±0.73
Total (95% CI)
Test for overall effect: Z=0.98 (p=0.33) Favours placebo Favours vitamin C
102 112 100.0% –0.11 (–0.34–0.11)
FIGURE 4 Forest plot of comparison: vitamin C versus control (outcome: forced vital capacity).
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Three of the trials [15–17] were published before the introduction of the CONSORT guidelines in 1996
which could explain their poor reporting of randomisation method and blinding [34]. This globally low
level of methodological quality is a significant limitation of this review. Table 3 details the results of those
trials with positive results and their overall risk of bias score.
Discussion
This review identified 23 trials measuring the effectiveness of 19 CAMs in the treatment of asthma in
adults. Overall, this review found limited evidence that oral and topical CAMs have any effect on lung
function, symptom control, quality of life, asthma medication usage, healthcare utilisation and adverse
events. Meta-analysis was performed on magnesium, vitamin C and vitamin D, the results of which
indicated that neither magnesium, vitamin C or D were beneficial in improving the lung function of
asthma patients. Eight single trials showed improvement in lung function (table 3) and symptom control
but there was no overall trend in one outcome measure across trials. In addition, many of the trials had a
poor methodological quality, restricting the reliability and applicability of these results. These limitations
have been mirrored in previous reviews.
PASSALACQUA et al. [4] found positive results but were limited by “methodological flaws”, such as poor
randomisation, lack of blinding and no quantitative measurement. Many of the results derived in this
review described themselves as double-blind, placebo-controlled trials but on further investigation were
First author
[ref.] Total
Vitamin D Placebo Weight
Mean ± SD % pred Mean ± SD % pred
Mean difference
IV fixed (95% CI) % pred
Mean difference
IV fixed (95% CI) % pred
MARTINEAU [31]
NANZER [32]
Heterogeneity. Chi2=0.01, df=1 (p=0.93); I2=0% –10 100–5 5
81.6±18.5
68.1±19.83
125
12
Total
125
11
89.2%
10.8%
1.50 (–3.65–6.65)
2.20 (–12.56–16.96)
80.1±22.8
65.9±16.22
Total (95% CI)
Test for overall effect: Z=0.64 (p=0.53) Favours vitamin D Favours placebo
137 136 100.0% 1.58 (–3.28–6.44)
FIGURE 5 Forest plot of comparison: vitamin D versus control (outcome: forced expiratory volume in 1 s).
TABLE 4 Risk of bias summary: author’s judgement for each risk of bias domain and included study
First author [ref.] Sequence
generation
Allocation
concealment
Blinding of
participants and
personnel
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Other
bias
ABIDI [11] + − − ? + + +
CASTRO [33] + ? + ? + + +
EMELYANOV [12] + ? + ? + + +
FOGARTY [24] + ? + ? + + +
GOVINDAN [13] ? ? − − ? + +
GVOZDJAKOVA [14] ? ? − ? ? − +
HASSELMARK [15] + ? + ? + − +
HILL [25] + ? + ? − + +
HONMA [16] ? ? + ? − + +
KASLOW [17] ? ? + ? + + +
KELLY-PIEPER [29] ? ? + ? − − −
KHAYYAL [18] ? ? ? ? + + +
MARTINEAU [31] + ? + ? + + +
MOREIRA [27] + + + ? − + +
NADI [26] ? ? + ? ? + +
NANZER [32] + + + + + + +
OKAMOTO [28] ? ? ? ? ? − +
PEARSON [19] + ? + + + + +
THOMAS [20] ? ? + ? − + +
THOREN [21] ? ? + ? + + +
URATA [22] ? ? + ? − + +
WEN [30] ? ? + ? + + −
ZHANG [23] + ? ? ? − + +
+: low risk; ?: unclear risk; −: high risk.
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actually of very low quality. The majority of included studies had predominantly unclear or high-risk
domains in their risk of bias assessment. This globally low level of methodological quality is a significant
limitation of this review.
This review found 10 of the 23 included trials had some positive results, which were both primary and
secondary outcome measures. In a review by HUNTLEY et al. [6], approximately half of the trials had some
positive outcomes, where the intervention group improved more than the placebo. Many of these findings
were from a single trial with a high risk of bias assessment and, similar to this review, must be taken in
this context. HUNTLEY et al. [6] also highlighted the problem of using products with non-standardised
quality and therefore even positive results for CAMs tested in multiple trials should be viewed critically.
Manufacturers of CAM compounds are not always required to prove the safety of their products [8],
which are often poorly standardised and may contain harmful substances [4]. The low number of reports
in included studies could be due to the search strategy of this review where the primary outcome of
interest was lung function. Therefore, some trials focusing on adverse events may not have met entry
criteria and been excluded. This deficit in information regarding adverse events and their frequency means
CAM cannot be recommended for use in routine clinical practice.
14 of the included CAMs were only tested in one trial, which often also had a small sample size. This
limited the data that could be pooled for meta-analysis and therefore the review. Furthermore, the type of
outcome measure, outcome measurement tool and study duration varied across trials. The search was
restricted to trials published in English after 1990, which assumes that no significant evidence was
published before this date or in another language and therefore trials may have been missed. Procedural
differences, participant compliance, smoking, concomitant medication usage and varying asthma severity
further limited comparison between trials, the reliability of results and the validity of this review.
Overall, good quality RCTs assessing the efficacy of CAM in the management of asthma are rare. The
included studies cover a wide range of outcomes and although this highlights the potential impact of CAM
in future practice, it is unclear which asthma-related outcome CAM benefits the most. This review does
not provide sufficient evidence to recommend any of the included CAM compounds for asthma. However,
it also does not demonstrate that they are ineffective and suggests a need for further, higher quality RCTs
with validated outcome measurement tools and formal safety assessments.
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